Item 7.01 Regulation FD Disclosures.

On June 16, 2020, Biomerica, Inc. ("Biomerica") issued a press release announcing that it has filed for FDA Emergency Use Authorization of its unique laboratory antibody test for COVID-19. The Company also announced that it has filed a provisional patent on technology to allow simplified blood collection of samples. A copy of Biomerica's press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 in its entirety.

The information contained in Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.




Item 8.01 Other Events.

On June 14, 2020, the Company filed for FDA Emergency Use Authorization (EUA) for an ELISA lab-based serology blood test for the detection of antibodies that identify if a person has been infected with the novel Coronavirus (COVID-19).

On April 21, 2020, the Company filed a provisional patent on technology to allow simplified blood collection of samples.




Item 9.01     Financial Statements and Exhibits



(d)     Exhibits.



 Number   Description

99.1      Press Release issued June 16, 2020.




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses